Iason GmbH has continued its refinancing efforts with local banks based on an IBR
The shareholders of Iason GmbH have completed a restructuring of the company and its refinancing efforts with local banks based on an IBR.
The Iason group produces radiopharmaceuticals and supplies special laboratory products to the target group "nuclear medicine" and "laboratory medicine" providing innovative products with the highest quality standards. The company has customers from all over Europe.
Oaklins' team in Austria assisted Iason with the preparation of the IBR (independent business review) and negotiations with local banks regarding refinancing possibilities.


Talk to the deal team

Related deals
A group of Chilean investors has acquired Farmacias Ahumada
A group of Chilean investors has acquired Farmacias Ahumada S.A. from Walgreens Boots Alliance.
Learn moreShield Therapeutics has completed a fundraising
Shield Therapeutics plc has raised funds to bolster the expansion of ACCRUFeR®, the sole FDA-approved therapy for iron deficiency and to drive the business. Additionally, it positions the company for further investments.
Learn moreHaydale Graphene Industries has completed a fundraising
Haydale Graphene Industries PLC has raised funds to continue to develop the ongoing commercialization of its proprietary HDPlas® plasma functionalization process.
Learn more